FEMASYS INC (FEMY) News

FEMASYS INC (FEMY): $1.23

0.05 (+4.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter FEMY News Items

FEMY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest FEMY News From Around the Web

Below are the latest news stories about FEMASYS INC that investors may wish to consider to help them evaluate FEMY as an investment opportunity.

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

-- FemCath™ is the first FDA-cleared intrauterine catheter that allows for selective evaluation of a fallopian tube with contrast -- -- FemCath is used in conjunction with FemVue as a baseline diagnostic test for infertility -- ATLANTA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced

Yahoo | December 19, 2022

Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons

--FemCerv®, the first endocervical tissue sampler of its kind in the detection of cervical cancer, was well-received after being presented at the AAGL conference attended by over 2,000 leading gynecologic specialists-- ATLANTA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today reported that it h

Yahoo | December 12, 2022

Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design

--FemaSeed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility--ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that it has completed over 25% of its targeted enrollment (214 patient fertility cycles) in its FemaSeed® de novo tria

Yahoo | November 29, 2022

Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference

ATLANTA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present at the Piper Sandler 34th Annual Healthcare Conference being held November 29 through December 1, 2022 at the Lotte New York Palace Hotel in

Yahoo | November 21, 2022

Analysts’ Top Technology Picks: AppLovin (APP), Femasys (FEMY)

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on AppLovin (APP – Research Report) and Femasys (FEMY – Research Report) with bullish sentiments. AppLovin (APP) Goldman Sachs analyst Eric Sheridan maintained a Buy rating on AppLovin on November 10 and set a price target of $33.00. The company's shares closed last Friday at $16.94, close to its 52-week low of $13.20. According to TipRanks.

Brian Anderson on TipRanks | November 13, 2022

Femasys Third Quarter 2022 Earnings: Misses Expectations

Femasys ( NASDAQ:FEMY ) Third Quarter 2022 Results Key Financial Results Net loss: US$2.98m (loss widened by 32% from...

Yahoo | November 12, 2022

Maxim Group Sticks to Their Buy Rating for Femasys (FEMY)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Femasys (FEMY - Research Report) yesterday and set a price target of $5.00. The company's shares opened today at $1.20.According to TipRanks, McCarthy is an analyst with an average return of -39.6% and a 14.32% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Immutep, and Actinium Pharmaceuticals.Femasys has an analyst consensus of Moderate Buy, with a price target consensus of $5.00, which is a 316.67% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.

Austin Angelo on TipRanks | November 11, 2022

H.C. Wainwright Reaffirms Their Buy Rating on Femasys (FEMY)

E ratio of -1.44.

Austin Angelo on TipRanks | November 11, 2022

Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates

Femasys Inc. (FEMY) delivered earnings and revenue surprises of -8.70% and 13.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

--FemaSeed® de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility-- --Company remains on track to file an Investigational Device Exemption (IDE) for a pivotal trial to support a Pre-Market Authorization (PMA) for FemBloc® in Q1 2023-- --FemCerv® now commercially available with FemCath™ launch expected by year-end-- ATLANTA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwi

Yahoo | November 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.485 seconds.